All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following hospital-treated infection patient populations:
- Diagnosed HCAP events due to E.coli
- Diagnosed BSI events due to Klebsiella
- Diagnosed BSI events due to E.coli
- Diagnosed BSI events due to Pseudomonas
- Diagnosed BSI events due to other gram-negative
- Diagnosed cIAI events due to E.coli
- Diagnosed cIAI events due to Pseudomonas
- … and many more (details available on request).
Note: Coverage may vary by country and region.
- Hospital-Treated Gram-Negative Infections - Epidemiology - Americas Data
Author(s): Fjoralba Kristo, MD, MPH ; Lade Ayodele
Fjoralba Kristo has expertise in forecasting infectious diseases and chronic diseases in both the mature and global markets. She has extensive academic experience with quantitative and qualitative research methods.
Prior to joining Decision Resources Group, she completed a postdoctoral fellowship at University of Kentucky, Division of Cardiovascular Medicine, and more recently worked as Research Scientist at Massachusetts General Hospital, where she investigated mechanisms of inflammation in cardiovascular diseases. Fjoralba holds an MPH degree from Boston University School of Public Health, concentrating in Epidemiology and Biostatistics, and a medical degree from University of Medicine, Bucharest, Romania.
Dr. Ayodele has expertise in forecasting disease populations and is an epidemiology expert in chronic diseases including cancers and cardiovascular diseases, in both the major and emerging pharmaceutical markets.
Prior to joining Decision Resources Group, she researched antiretroviral therapy funding, availability and access at the Clinton Foundation Center for Strategic HIV Operations Research. More recently, she was a Medical Innovation and Leadership fellow at Blue Cross Blue Shield of Massachusetts, where she researched and developed strategic plans on health care utilization and quality improvement. Dr. Ayodele holds a Master in Public Health degree (quantitative methods concentration) from Harvard and a medical degree from the University of Ibadan in Nigeria. She is currently pursuing a Ph.D. in epidemiology at Boston University School of Public Health with a focus in pharmacoepidemiology.